Voniza 10 mg Tablet 2 x 7’s Pack

Voniza 10 mg Tablet 2 x 7’s Pack

Voniza 10 mg Tablet is a medication designed to treat various gastrointestinal conditions. It is primarily used for the treatment of gastric ulcers, duodenal ulcers, and reflux esophagitis. This tablet can also help prevent the recurrence of gastric or duodenal ulcers during low-dose aspirin administration and the prevention of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs).

Each pack contains two blister packs of 7 tablets each, ensuring you have a sufficient supply for your treatment needs. The active ingredient in Voniza 10 mg Tablet is Vonoprazan, which works by reducing stomach acid production to help heal and prevent ulcers.

Key Uses:

• Gastric Ulcer: Treats gastric ulcers by reducing stomach acid.
• Duodenal Ulcer: Manages duodenal ulcers by minimizing acid production.
• Reflux Esophagitis: Treats reflux esophagitis by reducing acid in the esophagus.
• Prevention of Recurrence: Helps prevent the recurrence of gastric or duodenal ulcers during low-dose aspirin use.
• NSAID-Induced Ulcers: Prevents ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs).

Side Effects:

Common side effects include abdominal pain, diarrhea, constipation, flatulence, dizziness, fatigue, and rash. If you experience severe diarrhea, it is recommended to discontinue use.

Precautions:

Use caution in patients with severe hepatic impairment. Avoid concurrent use with certain medications like atazanavir and rilpivirine. Consider the risk of Clostridium difficile-associated diarrhea.

Dosage:

The recommended dosage is typically once daily, administered orally before a meal. Always follow the prescribed dosage and consult your healthcare provider if you have any questions or concerns.

Contraindications:

Voniza Tablet 10 mg is contraindicated in patients with a known hypersensitivity to Vonoprazan or any other component of the formulation. It should not be used concurrently with certain medications, such as nelfinavir and rifampicin, due to the risk of reduced efficacy or increased adverse effects.